Unione Europea - italiano - EMA (European Medicines Agency)

alnylam netherlands b.v. - vutrisiran sodium - amyloid neuropathies, familial - altri farmaci sul sistema nervoso - treatment of hereditary transthyretin-mediated amyloidosis (hattr amyloidosis) in adult patients with stage 1 or stage 2 polyneuropathy.

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

alnylam switzerland gmbh - vutrisiranum natricum - soluzione iniettabile in siringa preriempita - suspension: vutrisiranum natricum 25 mg pro dosi, natrii dihydrogenophosphas dihydricus, dinatrii phosphas dihydricus, natrii chloridum, aqua ad iniectabile, acidum phosphoricum, natrii hydroxidum, pro praeparatione, natrium < 23 mg/ml. - amvuttra wird zur behandlung der hereditären transthyretin-amyloidose (hattr-amyloidose) bei erwachsenen patienten mit polyneuropathie der stadien 1 oder 2 angewendet - trapianto: gentherapieprodukt